The 2026 report highlights top drivers of global pharmaceutical sales, M&A, and China’s continued impact on the industry June 23, 2026 09:00 ET  | Source: Evaluate LONDON, June 23, 2026 (GLOBE NEWSWIRE) — Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2026 World Preview Report, providing updated insights for the global pharmaceutical market. […]

June 22, 2026 03:00 ET  | Source: Boehringer Ingelheim Limited Ingelheim, Germany and Ridgefield, Conn – Boehringer Ingelheim is advancing biomarker-informed approaches and extending precision care across multiple cancers and stages of disease, reinforcing its ambition to bring unprecedented impact and improve long-term outcomes where unmet need remains high.4,5,6 The company has initiated two Phase III clinical trials within

Global CRO expands its operational footprint into Singapore and Malaysia, strengthens China presence, and grows India operations – creating a powerhouse in the Asia Pacific region June 19, 2026 06:30 ET  | Source: Avance Clinical ADELAIDE, Australia, June 19, 2026 (GLOBE NEWSWIRE) — Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced a

June 18, 2026 17:00 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2026 Aide Memoire is available on the “Investors” page on its website. Q2 2026 Aide Memoire Teva has compiled this document with public information

June 18, 2026 16:57 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric

June 18, 2026 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2026 financial results on Wednesday, July 29, 2026, at 7:00 a.m. ET. Following

June 18, 2026 09:03 ET  | Source: SK pharmteco Inc. RANCHO CORDOVA, Calif., June 18, 2026 (GLOBE NEWSWIRE) — SK pharmteco today announced a collaborative agreement with the Orphan Therapeutics Accelerator (OTXL), a non-profit, biotech focused on completing development and enabling access to stalled rare disease treatments, to support the advancement of novel therapeutic programs. The strategic partnership is built on

June 18, 2026 07:45 ET  | Source: Curium BOSTON, June 18, 2026 (GLOBE NEWSWIRE) — Curium™ is pleased to announce that it has prevailed in the patent dispute brought by Novartis subsidiary Advanced Accelerator Applications against Curium™ concerning Curium’s Lutetium Lu 177 dotatate product. In the court decision issued yesterday by the Delaware U.S. District Court, Justice

June 18, 2026 04:05 ET  | Source: Boehringer Ingelheim Limited Not intended for UK and US audiences  Ingelheim, Germany – Long-term survival modeling of Boehringer Ingelheim’s oral preferential PDE4B inhibitor, nerandomilast, predicts the therapy could extend survival by up to 5.4 years in adults with idiopathic pulmonary fibrosis (IPF) and up to 3.3 years in adults with progressive

June 16, 2026 08:30 ET  | Source: Optimi Health Corp. Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi’s psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country’s Authorized Prescriber Scheme

June 15, 2026 11:04 ET  | Source: BLUMM KNOWHOW S.R.L A great celebration of sport and community, with d’Annunzio University’s “sea of blue” among the most visible features of the 26th edition of the Chieti Night Run. The University of Chieti-Pescara took part with 262 entrants, including students and staff, bringing a strong message of wellbeing, community

June 14, 2026 18:05 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating

Leading allergy experts to convene in Istanbul to explore how science, prevention and policy can reduce the global impact of allergic diseases June 12, 2026 01:00 ET  | Source: European Academy of Allergy and Clinical Immunology ZURICH, June 12, 2026 (GLOBE NEWSWIRE) — As allergic diseases continue to affect hundreds of millions of people worldwide and place

June 11, 2026 04:36 ET  | Source: Global Liver Institute Washington, D.C., June 11, 2026 (GLOBE NEWSWIRE) — Global Fatty Liver Day 2026 comes at a pivotal moment for liver health worldwide. Following the adoption of the landmark World Health Organization (WHO) Resolution on Reducing the Burden of Noncommunicable Diseases, communities around the world are increasingly recognizing steatotic liver disease (SLD)

June 11, 2026 03:04 ET  | Source: Curium BOSTON, June 11, 2026 (GLOBE NEWSWIRE) — Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., patient dosing has been completed in the registrational Phase 2 clinical trial for 64Cu-PSMA-I&T in Japan. 64Cu-PSMA-I&T is a PET radiopharmaceutical targeting PSMA. 64Cu-PSMA-I&T is being assessed as a PET agent labeled